Scienture Holdings, Inc. (SCNX), a holding company for specialty pharmaceutical businesses, has entered into a securities purchase agreement with institutional investors to sell 3,225,000 shares of common stock at $1.20 per share.
The registered direct offering is expected to raise approximately $3.9 million in gross proceeds before fees and expenses and is scheduled to close on August 15, 2025, subject to customary conditions.
Proceeds will support Scienture's efforts to develop and distribute novel specialty pharmaceutical products targeting unmet market needs.
SCNX currently trades at $1.22 or 45.0450% lower on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.